RxSight, Inc. (NASDAQ:RXST) Insider Sells $153,045.45 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.29, for a total value of $153,045.45. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,082,305.34. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Performance

NASDAQ RXST traded up $0.89 during trading hours on Monday, hitting $49.43. The company had a trading volume of 436,551 shares, compared to its average volume of 484,350. The business has a 50 day moving average of $51.15 and a 200-day moving average of $53.88. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54. The company has a market cap of $1.83 billion, a PE ratio of -38.72 and a beta of 1.22.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The firm’s revenue was up 67.6% compared to the same quarter last year. Sell-side analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RxSight

Institutional investors have recently modified their holdings of the business. Amalgamated Bank grew its position in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock worth $473,000 after buying an additional 242 shares during the last quarter. RiverPark Advisors LLC increased its position in RxSight by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after acquiring an additional 297 shares during the period. CWM LLC increased its position in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after acquiring an additional 371 shares during the period. Finally, Arizona State Retirement System raised its stake in RxSight by 5.0% during the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock valued at $467,000 after acquiring an additional 373 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on RXST shares. Stifel Nicolaus cut their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, BTIG Research lifted their price target on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.